De novo and Acquired Resistance Mutations in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) undergoing Treatment with Abiraterone Acetate or Enzalutamide in Routine Clinical Care

Trial Profile

De novo and Acquired Resistance Mutations in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) undergoing Treatment with Abiraterone Acetate or Enzalutamide in Routine Clinical Care

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Oct 2017 New trial record
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top